





## Claims

1. A compound of formula I



wherein

$R_1$  is a residue of formula (a), (b) or (c)



$R_2$  is  $-(CR_{22}R_{23})_{1-3}-$  or  $-C(O)-$ ;

each of R<sub>3</sub> and R<sub>8</sub> independently is S; O; or NR<sub>24</sub>;

each of R<sub>4</sub> and R<sub>5</sub> independently is optionally R<sub>25</sub>-substituted C<sub>3</sub>-C<sub>12</sub> cycloalkyl, C<sub>1</sub>-C<sub>12</sub> alkyl or saturated C<sub>8-12</sub> polycyclic residue; or optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>alkyl or heteroaryl; wherein up to 4 carbon atoms of R<sub>4</sub> and/or R<sub>5</sub> are optionally substituted by S, O or NR<sub>24</sub>;

R<sub>6</sub> is H; C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>3</sub>-C<sub>6</sub> cycloalkyl; or optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>alkyl or heteroaryl;

$R_7$  is  $CR_{28}$  or  $N$ ;

R<sub>9</sub> is a direct bond; -(CR<sub>22</sub>R<sub>23</sub>)<sub>1-2</sub>-; or NR<sub>24</sub>;

each of R<sub>10-23</sub> and R<sub>28</sub> independently is H; F; Cl; Br; C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub> halogenoalkyl; C<sub>3</sub>-C<sub>6</sub> cycloalkyl; optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl or heteroaryl; CONR<sub>29</sub>R<sub>30</sub>; COOR<sub>29</sub>; CN; NO<sub>2</sub>; or OR<sub>31</sub>; or

two of R<sub>10-19</sub> which are attached to the same carbon atom, together with the carbon atom to which they are attached, form a 3-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S; or

R<sub>17</sub> and R<sub>18</sub>, together with the C atoms to which they are attached, form a 4-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S; or

R<sub>20</sub> and R<sub>21</sub>, together with the carbon atoms to which they are attached, form an optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl or heteroaryl;

each of R<sub>24</sub>, R<sub>29</sub> and R<sub>30</sub> independently is H; C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub> halogenoalkyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl; or optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>alkyl or heteroaryl;

R<sub>25</sub> represents 1 to 4 substituents each independently having one of the significances given for R<sub>10-23</sub> above;

R<sub>26</sub> represents 1 to 4 substituents each independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>1</sub>-C<sub>6</sub> hydroxyalkyl; C<sub>2</sub>-C<sub>6</sub> alkoxyalkyl; C<sub>1</sub>-C<sub>6</sub> halogenoalkyl; C<sub>3</sub>-C<sub>6</sub> cycloalkyl; C<sub>2</sub>-C<sub>6</sub> alkenyl; C<sub>3</sub>-C<sub>6</sub> cycloalkenyl; C<sub>2</sub>-C<sub>6</sub> alkynyl; aryl; heteroaryl; heteroaryl N-oxide; F; Cl; Br; I; OH; OR<sub>4</sub>; CONH<sub>2</sub>; CONHR<sub>4</sub>; CONR<sub>4</sub>R<sub>4</sub>; OC(O)R<sub>4</sub>; OC(O)OR<sub>4</sub>; OC(O)NHR<sub>4</sub>; OC(O)NR<sub>4</sub>R<sub>4</sub>; OSO<sub>2</sub>R<sub>4</sub>; COOH; COOR<sub>4</sub>; CF<sub>3</sub>; CHF<sub>2</sub>; CH<sub>2</sub>F; CN; NO<sub>2</sub>; NH<sub>2</sub>; NHR<sub>4</sub>; NR<sub>4</sub>R<sub>4</sub>; NHC(O)R<sub>4</sub>; NR<sub>4</sub>C(O)R<sub>4</sub>; NHC(O)NHR<sub>4</sub>; NHC(O)NH<sub>2</sub>; NR<sub>4</sub>C(O)NHR<sub>4</sub>; NR<sub>4</sub>C(O)NR<sub>4</sub>R<sub>4</sub>; NHC(O)OR<sub>4</sub>; NR<sub>4</sub>C(O)OR<sub>4</sub>; NHSO<sub>2</sub>R<sub>4</sub>; N(SO<sub>2</sub>R<sub>4</sub>)<sub>2</sub>; NR<sub>4</sub>SO<sub>2</sub>R<sub>4</sub>; SR<sub>4</sub>; S(O)R<sub>4</sub>; SO<sub>2</sub>R<sub>4</sub>; Si(CH<sub>3</sub>)<sub>3</sub> and B(OC(CH<sub>3</sub>)<sub>2</sub>)<sub>2</sub>;

R<sub>27</sub> represents two adjacent substituents which form an annulated 4-7 membered nonaromatic ring optionally containing up to two heteroatoms selected independently from N, O and S;


R<sub>31</sub> is C<sub>1</sub>-C<sub>6</sub> alkyl; C<sub>3</sub>-C<sub>7</sub> cycloalkyl; optionally R<sub>26</sub>- and/or R<sub>27</sub>-substituted aryl, arylC<sub>1-4</sub>alkyl or heteroaryl; or CF<sub>3</sub>;

or a pharmaceutically acceptable salt thereof.


2. A compound according to claim 1 which is selected from 1,3-Dicyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothioureia, 1-Cyclohexyl-3-cyclopentyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothioureia, 1-Cycloheptyl-3-cyclohexyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothioureia, 1,3-Dicycloheptyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothioureia, 1-Cyclohexyl-3-cyclooctyl-2-(5,6-dihydro-

imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-Dicyclohexyl-2-(6,6-dimethyl-5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea, 1,3-Dicyclooctyl-2-(5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea and 1,3-Dicycloheptyl-2-(6,6-dimethyl-5,6-dihydro-imidazo[2,1-b]thiazol-3-ylmethyl)-isothiourea.

3. A pharmaceutical composition comprising a compound according to claim 1 in free form or in a pharmaceutically acceptable salt form in association with a pharmaceutically acceptable diluent or carrier therefor.
4. Use of a compound according to claimed in claim 1 in free form or in a pharmaceutically acceptable salt form, for the manufacture of a medicament to prevent or treat disorders or diseases mediated by interactions between chemokine receptors, acute or chronic transplant rejection, inflammatory diseases, autoimmune diseases or proliferative diseases.
5. Use of a compound according to claimed in claim 1 in free form or in a pharmaceutically acceptable salt form, for the manufacture of a medicament to prevent or inhibit tumor invasiveness, symptoms associated with tumor growth, metastatic spread of tumours, tumor-associated angiogenesis or growth of micrometastases.
6. Use of a compound as claimed in claim 1 or in claim 2, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament in preventing or combating an infectious diseases, in particular viral infections or progression of AIDS.
7. A process for preparing a compound of formula I comprising reacting a compound of formula II



with a compound of formula III



wherein  $R_1$  to  $R_6$  are as defined in claim 1 and  $R_{32}$  is a leaving group;

and optionally converting a resultant compound of formula I obtained in free form to a salt form or vice versa.

8. A pharmaceutical combination comprising a compound according to claim 1 or claim 2 in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressive, immunomodulating, anti-inflammatory, antiproliferative, antineoplastic, chemotherapeutic, anti-infective, anti-viral, and antibiotic agents, and agents for the treatment of acute myeloid leukemia.

9. Combination according to claim 8 comprising an antiretroviral agent, in particular an anti-HIV agent.

10. Use of a combination according to claim 9 for the manufacture of a medicament for preventing or combating an infectious disease, in particular viral infection or progression of AIDS.

11. A method of treatment or prevention of any of the following conditions:

- i) disorders or diseases mediated by interactions between chemokine receptors,
- ii) acute or chronic transplant rejections,
- iii) inflammatory or autoimmune diseases,
- iv) proliferative diseases,
- v) symptoms associated with tumor invasiveness or tumor growth,
- vi) metastatic spreads of tumours, tumor-associated angiogenesis and growths of micrometastases,
- vii) infectious diseases, in particular viral infections, in particular binding or entry of HIV virus, or progression of AIDS,

comprising administering to said subject a therapeutically effective amount of a compound according to claim 1 or claim 2, or a or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 3.